Complement C1 Inhibitor Protein: all 35 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of Conestat Alfa for ACE-Induced AngioedemaNot yet recruitingNCT06679426Phase 3
• Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)RecruitingNCT06359782Phase 2
• Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19CompletedNCT04530136Phase 2Results posted
• Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant RecipientsTerminatedNCT03221842Phase 3Results posted
• C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft RejectionCompletedNCT02936479Phase 2Results posted
• A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedNCT02316353Phase 3Results posted
• Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)CompletedNCT02251041Phase 2Results posted
• A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedNCT02247739Phase 2Results posted
• C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRICompletedNCT02134314Phase 1/2Results posted
• C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica ExacerbationCompletedNCT01759602Phase 1Results posted
• Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedNCT01359969Phase 2Results posted
• Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent RejectionCompletedNCT01134510Phase 1/2Results posted
• C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT01005888Phase 3Results posted
• A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCompletedNCT00851409Phase 2Results posted
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00462709Phase 3Results posted
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00438815Phase 3Results posted
• C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)CompletedNCT00292981Phase 3Results posted
• C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00289211Phase 3Results posted
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262301Phase 3Results posted
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00225147Phase 2/3Results posted
• Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) AttacksCompletedNCT00168103Phase 2/3Results posted
• Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)CompletedNCT06690047Phase 4
• Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve ImplantationCompletedNCT05145283Phase 2
• Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 InfectionCompletedNCT04705831Phase 2
• Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19TerminatedNCT04414631Phase 2
• RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft FunctionStatus unknownNCT03791476Phase 1
• A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG InfusionsCompletedNCT03576469Phase 4
• C1-inhibitor in Allergic ASThma PatientsTerminatedNCT03051698Phase 4
• Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk SubjectsCompletedNCT02869347Phase 2
• In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR IICompletedNCT01766414Phase 3
• Research Into the Effect of a Clot-dissolving Agent and Its InhibitorTerminatedNCT01694381Early Phase 1
• Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic FractureTerminatedNCT01275976Phase 3
• In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human EndotoxemiaCompletedNCT00785018Not applicable
• Berinert P Study of Subcutaneous Versus Intravenous AdministrationCompletedNCT00748202Phase 3
• Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema SubjectsCompletedNCT00432510Phase 1

← Complement C1 Inhibitor Protein overview